Ioversol

Ioversol
Clinical data
Trade names	Optiray
AHFS/Drugs.com	Multum Consumer Information
Pregnancy; category	AU: B1; ;
ATC code	V08AB07 (WHO) ;
Legal status
Legal status	AU: Unscheduled; US: WARNING;
Pharmacokinetic data
Protein binding	Low
Metabolism	None
Elimination half-life	90 min
Excretion	Kidneys
Identifiers
	IUPAC name 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	87771-40-2 ;
PubChem CID	3741;
DrugBank	DB09134 ;
ChemSpider	3610 ;
UNII	N3RIB7X24K;
KEGG	D01555 ;
ChEMBL	ChEMBL1200614 ;
CompTox Dashboard (EPA)	DTXSID2045521 ;
ECHA InfoCard	100.118.911
Chemical and physical data
Formula	C18H24I3N3O9
Molar mass	807.115 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO;
	InChI InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33) ; Key:AMDBBAQNWSUWGN-UHFFFAOYSA-N ;
	(what is this?) (verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.^[2]^[3]

References

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
^ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[Medscape-2] "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.

[Chen-3] Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

[1]

[2]

[3]